Genomix Molecular Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.52 M
- Company Age 18 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.90 M
- Revenue Growth -9.34%
- Profit Growth 79.93%
- Ebitda 102.03%
- Net Worth -1.61%
- Total Assets -27.54%
About Genomix Molecular Diagnostics
Genomix Molecular Diagnostics Private Limited (GMDPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 January 2007 and has a history of 18 years and one month. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.52 M.
The company currently has active open charges totaling ₹2.90 M.
Bilhan Polavarapu, Vijay Kanthamneni, and Rathnagiri Polavarapu serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85110TG2007PTC052224
- Company No.
052224
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jan 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Genomix Molecular Diagnostics Private Limited offer?
Genomix Molecular Diagnostics Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Corona Test Kit, Rapid Test Kit.
Who are the key members and board of directors at Genomix Molecular Diagnostics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bilhan Polavarapu  | Director | 18-Aug-2021 | Current |
| Vijay Kanthamneni | Director | 03-Jan-2007 | Current |
Rathnagiri Polavarapu  | Director | 03-Jan-2007 | Current |
Financial Performance of Genomix Molecular Diagnostics.
Genomix Molecular Diagnostics Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.34% decrease. The company also saw a substantial improvement in profitability, with a 79.93% increase in profit. The company's net worth dipped by a decrease of 1.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genomix Molecular Diagnostics?
In 2023, Genomix Molecular Diagnostics had a promoter holding of 97.12% and a public holding of 2.88%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Genomix Healthcare (India) Private LimitedRathnagiri Polavarapu is a mutual person
Genomix Carl Private LimitedBilhan Polavarapu and Rathnagiri Polavarapu are mutual person
Charges (Loans)
₹2.90 M
₹0
Charges Breakdown by Lending Institutions
- Department Of Biotechnology : 0.29 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Sep 2009 | Department Of Biotechnology | ₹2.90 M | Open |
How Many Employees Work at Genomix Molecular Diagnostics?
Genomix Molecular Diagnostics has a workforce of 7 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genomix Molecular Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genomix Molecular Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
